LL 37

Biological Activity

LL 37 is an antimicrobial peptide derivative of human cathelicidin. Induces FPRL1-mediated chemotaxis of human neutrophils, monocytes and T cells in vitro. Promotes wound healing following skin-targeted electroporation of a plasmid encoding hCAP-18/LL-37 in mice. LL 37 reduces SARS-CoV-2 infection by blocking the receptor binding domain of the S1 spike protein (K_d = 11.2 nM) and by binding to ACE2 (K_d = 25.5.nM). LL 37 inhibits SARS-CoV-2 pseudovirion infection (IC₅₀ = 4.74 μg/mL) in vitro and in vivo. Also triggers apoptosis in colon cancer cells. Cell permeable.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Spotlight on human LL-37, an immunomodulatory peptide with promising cell-penetrating properties.
   Seil et al.
   Pharmaceuticals, 2010;3:3435
2. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells.
   Yang et al.
   J.Exp.Med., 2000;192:1069
3. Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing.
   Steinstraesser et al.
   Mol.Ther., 2014;22:734
4. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer.
   Ren et al.
   Cancer Res., 2012;72:6512

Product Datasheets